Clinical observation of escitalopram combined with risperidone and EEG biofeedback in the treatment of schizophrenia
Objective:To explore the application value of escitalopram combined with risperidone-assisted electroencephalogram(EEG)biofeedback therapy in patients with schizophrenia(SCH).Methods:One hundred patients with SCH admitted to our hospital between August 2021 and August 2023 were selected and randomly divided into two groups(50 cases each)using a random number table method.The control group was treated with oral escitalopram combined with risperidone,and the initial dose of escitalopram was 5 mg/day,which was increased to 15 mg/d within two weeks,once a day.The initial dose of risperidone was 1 mg/day,once a day,which was increased to 4～6 mg/d,twice a day,within 2 weeks.In the observation group,the EEG biofeedback treatment was added,and the supporting electrodes of the EEG biofeedback instrument were affixed according to the requirements.The instrument was then used to obtain the patients'brainwaves and conduct a corresponding analysis.The θ and β waves were adjusted according to the situation,and the EMG value was adjusted according to tolerance so that the θ waves were controlled at 4～8 Hz and the β wave at 15～20 Hz for 30 min.The two groups were treated for eight weeks,and the efficacy and safety of the two groups were compared.Results:The total effective rate of the observation group was higher than that of the control group,and the differences were statistically significant(P＜0.05).There was no statistically significant difference in the disease symptoms between the two groups before treatment(P＞0.05).After treatment,the PANSS scores of both groups were lower than before treatment,and the PANSS scores of the observation group were significantly lower than those of the control group(P＜0.05).There was no statistically significant difference in cognitive and social functions between the two groups before treatment(P＞0.05).After treatment,the MMSE and SSPI scores of both groups were higher than before treatment,and the MMSE and SSPI scores of the observation group were significantly higher than those of the control group(P＜0.05).There was no statistically significant difference in quality of life between the two groups before treatment(P＞0.05).After treatment,the SF-36 scores of both groups were higher than before treatment,and the SF-36 scores of the observation group were significantly higher than those of the control group(P＜0.05).There were no statistically significant differences in adverse reactions between the two groups(P＞0.05).Conclusions:The combination of EEG biofeedback therapy with escitalopram and risperidone improved the efficacy of SCH,accelerated the disappearance of disease symptoms,alleviated cognitive and social function impairment,and was safe and feasible.
schizophreniaescitalopramrisperidoneEEG biofeedbackcognitive function
万方数据
维普
